Gray R, et al. - Investigators analyzed 37,298 females to ascertain the relative advantages and hazards of dose-intense and standard-schedule chemotherapy in early breast cancer cases. They compared 2-weekly vs standard 3-weekly schedules and observed trials comparing the sequential vs concurrent administration of anthracycline and taxane chemotherapy. They increased the dose intensity of adjuvant chemotherapy by shortening the interval between treatment cycles. They also prescribed individual drugs sequentially rather than giving the same drugs concurrently. A moderate reduction in the 10-year risk of recurrence and death from breast cancer without increasing mortality from other causes was noted.